Skip to main content

Albatroz Therapeutics

Albatroz Therapeutics develops first-in-class antibodies targeting a novel component of the extracellular matrix. This approach addresses significant challenges in human health by focusing on the integrity of this biological structure. The company's initial therapeutic focus areas include oncology and inflammatory diseases.

Traction 9/10
Singapore · HQ
Founded 202161K+ followers
  • Biotechnology
Updated 23 months ago

Funding

Raised to date

$3.5MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.

Funding rounds are not available yet.

Founders

1 founder

Frederic Bard

CEO

Product

Features

  • Albatroz Therapeutics develops first-in-class antibodies targeting a novel component of the extracellular matrix. This approach addresses significant challenges in human health by focusing on the integrity of this biological structure. The company's initial therapeutic focus areas include oncology and inflammatory diseases.
This profile is AI-generated and may contain inaccuracies.